Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma. Enke JS, Bundschuh RA, Wienand G, Reitsam NG, et al. J Nucl Med 2023 Jun 15:jnumed.123.265639. doi: 10.2967/jnumed.123.265639.

Read + Share

Amedeo Smart

Independent Medical Education

Enke JS, Bundschuh RA, Wienand G, Reitsam NG, et al. Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma. J Nucl Med 2023 Jun 15:jnumed.123.265639. doi: 10.2967/jnumed.123.265639.
PMID: 37321826